Airsculpt Technologies, Inc. (AIRS) · Nov 6, 2026 · Earnings
Miss — Revenue $31.9M vs ~$34.3M consensus; EPS -$0.10 vs -$0.03
AirSculpt earnings missed on revenue and EPS as case volumes fell, margins collapsed, and the company cut 2026 guidance again.
AirSculpt is trying to stabilize a 31-center premium body-contouring network while broadening into GLP-1-related procedures and repairing unit economics through marketing, new services, and tighter cost control. Before this filing, the company had already warned that 2026 revenue would land near the low end of its $151M-$157M range and had cut adjusted EBITDA guidance to $12M-$14M.
The quarter missed a low bar, not just the company’s own framing. Revenue was $31.9M versus roughly $34.3M consensus, while diluted EPS was -$0.10 versus an expected -$0.03; management itself said the quarter was “below expectations.” 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Highlights) | $31.9M (-8.7%) | $35.0M | ~$34.3M |
| Diluted EPS (Income Statement) | -$0.10 | -$0.15 | -$0.03 |
| Cases (Other Data) | 2,483 (-10.7%) | 2,780 | |
| Adjusted EBITDA (Other Data) | $0.4M (-87.1%) | $3.0M | |
| Adjusted EBITDA margin (Other Data) | 1.2% | 8.7% |
The core demand problem resurfaced hard. Cases fell 9.6% on a same-center basis, and the company’s 2.3% increase in revenue per case was nowhere near enough to offset lost volume. That reverses the stabilization narrative from the first half, when same-center cases had grown 1.0% in Q2 and 1.1% year to date.
Profitability deteriorated far more than the headline revenue decline suggests. Adjusted EBITDA dropped to $0.4M from $3.0M, with margin collapsing to 1.2% from 8.7%. The company says it is expanding GLP-1-related procedures, but this filing provides no evidence that initiative has yet offset weaker procedure demand. 〔1〕
The guidance cut confirms the weakness is expected to persist through year-end. The filing says guidance was reduced to reflect third-quarter performance continuing through year-end, but it does not disclose the revised revenue or adjusted EBITDA figures, so the size of the reset cannot be quantified from this filing alone. 〔2〕
The refinancing removes an immediate maturity wall but does not solve the operating problem. AirSculpt replaced the prior facility with a $39M senior secured term loan and $5M revolver maturing November 5, 2031, extending runway from the previously targeted 2027 maturity. But the new debt carries a 2.50% SOFR floor, margins as high as 7.75%, scheduled amortization, mandatory cash-flow sweeps, and tight leverage, fixed-charge, and liquidity tests. 〔3〕
Bottom line: This is a clear operating setback: demand weakened, adjusted EBITDA nearly disappeared, and management cut the outlook again. The refinancing buys time, but the business now has to stabilize volume before that extra runway becomes meaningful.
Q4 results and 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!